ANDA 212214, held by Novitium Pharma. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 212214 (Solifenacin Succinate), held by Novitium Pharma, was first approved by FDA on Sep 26, 2019, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 26, 2019 | Original application | Approved | None posted |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Rx |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Rx |
| Mar 25, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 26, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters